Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
2011

Combining Paclitaxel and Gefitinib for Lung Cancer Treatment

publication Evidence: moderate

Author Information

Author(s): Cheng Hua, An She-Juan, Dong Song, Zhang Yi-Fang, Zhang Xu-Chao, Chen Zhi-Hong, Jian-Su, Wu Yi-Long

Primary Institution: Guangdong Lung Cancer Institute; Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences

Hypothesis

The study investigates the sequence-dependent interaction between paclitaxel and gefitinib in EGFR-mutant non-small cell lung cancer cell lines.

Conclusion

The sequence of paclitaxel followed by gefitinib is an effective treatment combination for NSCLC cell lines with EGFR mutations.

Supporting Evidence

  • The sequence of paclitaxel followed by gefitinib produced the most potent antiproliferative effect in NSCLC cells.
  • Paclitaxel significantly increased EGFR phosphorylation compared to untreated controls.
  • The addition of gefitinib after paclitaxel treatment resulted in greater inhibition of EGFR phosphorylation.

Takeaway

This study shows that giving paclitaxel before gefitinib helps fight lung cancer better than giving them together or the other way around.

Methodology

The study evaluated the effects of different treatment sequences of paclitaxel and gefitinib on cell proliferation and EGFR signaling in NSCLC cell lines.

Limitations

The in vitro results may not directly correlate with clinical outcomes due to differences in drug interactions in patients.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-8722-4-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication